Detroit, MI Clinical Trials Report — April 2026

For Detroit residents considering participation in clinical research, April 2026 presents a critical window for those looking to join studies before enrollment concludes. Across the city, 49 clinical trials are slated to close within the next 90 days, indicating a need for prompt action from interested volunteers. This urgency is particularly relevant for healthy individuals, as 3 of these rapidly closing studies are still actively seeking participants without specific health conditions.

Act Now: Trials Nearing Enrollment Deadlines

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on various cancers and acute conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Primary peritoneal cancer (2 trials)
• Acute leukemia (2 trials)
• Fallopian tube cancer (2 trials)
• Solid tumor (2 trials)
• Breast cancer (2 trials)
• Acute respiratory distress syndrome (1 trial)
• Acute myeloid leukemia (1 trial)
• Acute biphenotypic leukemia (1 trial)
• Advanced NSCLC (1 trial)
• Advanced cancer (1 trial)

Individuals interested in these specific areas should explore their options without delay to potentially contribute to medical advancements.

New Opportunities in Detroit Research

This month, Detroit saw the opening of 6 new clinical trials, an increase from the 4 trials that launched in March 2026. While this signifies a growing research landscape, it's important to note that none of these new trials are currently accepting healthy volunteers. However, Detroit still offers 40 total trials actively recruiting healthy participants across various research areas.

April brings several high-profile new trials to Detroit, including significant Phase 2 and 3 studies from major sponsors and local institutions. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Novartis Pharmaceuticals is sponsoring NCT07517263, "An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)." This Phase 3 open-label extension study, designed for 5,700 participants, provides continued access to pelacarsen for those who completed the parent study, focusing on long-term safety and tolerability for cardiovascular disease and lipoprotein(a).
• Memorial Sloan Kettering Cancer Center is leading NCT07507643, "A Study of Methylprednisolone in People Having Liver Surgery." This Phase 3 study, aiming for 750 participants, investigates whether receiving methylprednisolone before hepatectomy can reduce post-surgical side effects like infections and shorten hospital stays.
• Incyte Corporation is launching NCT07522073, "A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma." This important Phase 3 oncology trial seeks 588 participants to evaluate the efficacy and safety of a new combination therapy for heptocellular cancer.
• Locally, Henry Ford Health System is sponsoring NCT07530172, "Radioembolization Versus External Radiation Therapy." This Phase 2 study, designed for 146 participants, will evaluate the efficacy and tolerability of transarterial radioembolization (TARE) versus stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma.

New trials this month are exploring a range of conditions, including behavioral symptoms, self-injurious behavior, cardiovascular disease, coronary artery disease, coronary calcification, and liver cancer. Drug trials account for 3 of the new studies, alongside 1 behavioral, 1 device, and 1 radiation trial.

Detroit's Leading Research Institutions

Detroit is home to significant research institutions that consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Henry Ford Hospital (141 trials)
• Karmanos Cancer Institute (97 trials)
• Henry Ford Health System (83 trials)
• Henry Ford Health (48 trials)
• Children's Hospital of Michigan (43 trials)
• Wayne State University/Karmanos Cancer Institute (43 trials)
• Research Site (38 trials)
• Henry Ford Health Saint John Hospital (36 trials)
• Wayne State University (25 trials)
• Barbara Ann Karmanos Cancer Institute (25 trials)
• Henry Ford Cancer Institute (13 trials)
• John D. Dingell VA Medical Center, Detroit, MI (9 trials)

These institutions, particularly the Henry Ford network and the Karmanos Cancer Institute, offer a broad spectrum of research, from oncology to general medical conditions, making them central to Detroit's clinical trial landscape. Overall, Detroit currently has 771 clinical trials recruiting across 210 research facilities.

Expanding Your Search: Nearby Michigan Cities

While Detroit offers a robust array of clinical trial opportunities, individuals may also find options in nearby communities within Michigan. Cities with active trials include Ann Arbor (12 trials), Troy (4 trials), Grand Rapids (1 trial), Wyoming (1 trial), and Ypsilanti (1 trial). Exploring these nearby locations can broaden the possibilities for participation.

Who Can Participate?

Participation in clinical trials is open to a diverse range of individuals. Of the 6 new trials launched this month, 1 includes children and 6 include older adults, ensuring that various age groups have opportunities to contribute to medical science. No new trials this month are exclusively for female or male participants. Academic institutions, including Henry Ford Health System and the University of Michigan, along with industry sponsors like Incyte Corporation and Novartis Pharmaceuticals, continue to drive significant research efforts in the region.

As spring progresses, Detroit's research community will continue to focus on advancing medical knowledge through these diverse trials, offering residents numerous ways to contribute to future healthcare innovations.